Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Gemcitabine + Cisplatin + Amifostine in Bladder Cancer
NCT00006105Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Jun 2000
- Primary completion
- Nov 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amifostine in bladder cancer, sponsored by University of Chicago. Primary endpoint: Side effects of cisplatin/gemcitabine in combination with amifostine at 4 months. Started Jun 2000; status: completed.
02
Drugs
amifostine
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT00006105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006105.